IBO IMPACT BIOMEDICAL INC. Insider Trading

Director Chan Heng Fai Ambrose sold 1,689,693 shares (100% of holdings) for $1,122,919.96 across 7 transactions on Apr 2-4 at blended avg price of $0.66.

Chan Heng Fai Ambrose executed a complete exit from IBO over three trading days, selling 7 separate tranches totaling 1,689,693 shares for $1,122,919.96 and reducing his holdings to zero. The sales occurred at prices ranging from $0.58 to $0.96, with a blended average of $0.66, while the stock currently trades at $0.96—80.6% below its 52-week high of $4.96. The timing is notable: these sales follow a prior pattern at this ticker where three additional sells occurred on March 31 and April 1, suggesting an accelerating liquidation across four days. Against his cross-ticker track record of 16 prior buys averaging +25.2% gain over 30 days and +162.3% over 90 days, this complete exit from his sole measurable position at IBO is a material shift, particularly given the company's quarter with only $50,000.00 in revenue yet $4,241,000.00 in net income, highlighting potential earnings quality concerns that warrant scrutiny of the underlying business.

Director Chan Heng Fai Ambrose sold 2,526,918 shares (77.5% of holdings) across 4 transactions for $2,912,821.44; stock down 60.4% in 30 days, 63.0% in 90 days.

Director Chan Heng Fai Ambrose executed 4 separate sales totaling 2,526,918 shares for $2,912,821.44 between March 31 and April 1, with prices ranging from $0.98 to $1.45 and a blended average of $1.15. The current price of $0.57 represents an 88.5% decline from the 52-week high of $4.96 and marks a 60.4% drop over 30 days and 63.0% over 90 days—a dramatic deterioration in fundamental value after these sales. The company reported recent quarterly revenue of $50,000.00 against a market cap of $6,888,684.84, yet posted a $4,241,000.00 net income in the latest quarter despite being unprofitable over its most recent full fiscal year, a fundamental inconsistency that demands scrutiny. This appears to be a substantial liquidation of the director's position (from 3,260,976 to 734,058 shares, a net reduction of 77.5%), occurring as the stock has experienced severe downward price pressure post-transaction.

10% owner DSS, INC. sold 605,620 shares (605.6K shares) in 6 transactions across Mar 21-27 for $1,950,928.48 ($2.0M), reducing stake by -36.5%

DSS, INC., a 10% stakeholder, executed 6 separate sales totaling 605,620 shares for $1,950,928.48 across a 7-day window (March 21–27, 2025) at prices ranging from $2.50 to $3.30. This represents a -36.5% reduction in holdings, from 1,657,420 shares to 1,051,800 shares post-transaction. At a blended average price of $3.22, the insider was selling well above the current price of $1.52 (a $1.70 premium, or -69.4% from the 52-week high of $4.96). His prior 2 cross-ticker sells were well-timed (100% well-timed rate), with the most recent IBO sale on 2024-12-02 declining -45.5% over 90 days. However, context is critical: the company reported revenue of only $50,000.00 (latest quarter) against a market cap of $18,369,826.24 ($18.4M), and was unprofitable over its most recent full fiscal year. The timing and scale of this sale—executed at elevated prices relative to where the stock has since fallen—alongside the company's deteriorating fundamentals, merits investor attention.

10% owner DSS, INC. liquidates entire 53.1K share stake in IBO via 2 sales totaling 53,300 shares for $249,408.40

DSS, INC., a 10% holder, executed a complete exit of its position in Impact Biomedical, selling 53,300 shares (53.3K shares) across 2 separate transactions on 2024-12-02 and 2025-03-20 for $249,408.40, reducing holdings from 53.1K shares to zero. The timing of the larger sale on 2025-03-20 at $4.68 per share occurred within a context where the stock has posted significant recent momentum (+69.8% over 30 days, +151.8% over 90 days) and currently trades at $3.60, down 27.4% from its 52-week high of $4.96. This full liquidation by a significant shareholder represents a material reduction in insider ownership concentration and merits attention given the company's weak revenue base ($50.0K in the latest quarter), despite current profitability of $4.2M net income, and the insider's prior track record at this ticker (2 prior buys both showing negative 90-day returns) which shows no pattern of well-timed entries or exits at IBO.

CEO Frank D Heuszel bought 500 IBO shares at $2.26 on 2024-12-05; third purchase in 9 days amid -24.8% 30-day decline.

CEO Frank D Heuszel purchased 500 shares at $2.26, bringing his holdings to 97,344 shares post-transaction. This marks his third open-market buy in 9 days (prior purchases on 2024-11-27, 2024-11-26, and 2024-11-26), during a period when IBO's stock has declined 24.8% over the past 30 days and trades 28.3% below its 52-week high of $3.04. The company's fundamentals are mixed: while the latest quarter shows net income of $4,241,000.00, the company was unprofitable over its most recent full fiscal year, and quarterly revenue stands at $50,000.00. The concentrated buying pattern in early December warrants attention as an indicator of insider activity during price weakness, though the recency of all three purchases prevents 90-day outcome assessment.

CEO Frank D Heuszel bought 1,050 shares at blended average price of $2.61 on 2024-11-26.

Frank D Heuszel, CEO of Impact Biomedical, purchased 1,050 shares across 2 separate transactions (550 shares at $2.62 and 500 shares at $2.59) for a combined $2,738.75, increasing his holdings to 96,344 shares. The purchase occurred when the stock was trading at a 24.3% discount to its 52-week high and down 14.2% over the prior 30 days, suggesting the CEO acquired shares during a period of price weakness relative to recent history. However, Impact Biomedical reported a negative full-year net income despite current-quarter profitability ($4.2M quarterly net income), and the company's market cap of $26,459,096.50 with P/E of 23.00 indicates elevated valuation relative to its size and profitability trajectory. The magnitude of this purchase (1.1% addition to holdings) is modest against the CEO's existing 96.3K-share position, and his cross-ticker track record shows only 1 prior buy with no measurable timing outcomes yet available for evaluation.

CEO Frank D Heuszel bought 500 shares at $2.61 on 2024-11-27, second consecutive day purchase; stock -24.3% from 52-week high.

Frank D Heuszel, Chief Executive Officer of Impact Biomedical Inc., purchased 500 shares at $2.61 on 2024-11-27, following another purchase of 30 shares at the same price on 2024-11-26. The stock is currently trading at $2.30, down -24.3% from its 52-week high and down 30-day change: -14.2%. While the company reported a net income of $4.2M against revenue of $50.0K in the latest quarter (P/E of 23.00), it was unprofitable over its most recent full fiscal year. The total value of this transaction was $1,305.00 ($1.3K), representing a modest 0.5% increase to his holdings from 96.3K to 96.8K shares. Heuszel's cross-ticker track record shows only 2 prior buys, with insufficient measurable history at this specific ticker to establish a timing pattern.

10% owner DSS, INC. bought 1,000 shares of IBO at $2.33 (total $2,330.00)

DSS, INC., a 10% owner of Impact Biomedical Inc., purchased 1,000 shares at $2.33 on 2024-09-18, adding to existing holdings that now total 58,800 shares. This occurs in the context of a company trading at $2.52 just 4 trading days after its initial listing, with recent quarterly revenue of $50,000.00 but net income of -$884,000.00 and full-year profitability remaining negative. The purchase increases the insider's stake by 1.7% relative to pre-transaction holdings. Given the company's nascent public status, ongoing operating losses, and minimal revenue scale, investor attention should focus on whether this acquisition reflects meaningful confidence from an existing 10% holder or routine portfolio adjustments in an early-stage, unprofitable biomedical entity.

10% owner DSS Inc. buys 57,800 shares ($153.2K) in loss-making biomedical startup IBO (IPO day 3)

DSS, Inc., a 10% shareholder of Impact Biomedical Inc., purchased 57,800 shares across two transactions totaling $153,220.00 at blended average price $2.65 on 2024-09-16 and 2024-09-17. The company is in its third trading day following listing and is fundamentally unprofitable: quarterly revenue was $50,000.00 against net income of $-884,000.00, with negative net income over the most recent full fiscal year. The current price of $2.39 reflects a modest post-IPO pullback from the transaction prices ($2.69 and $2.40), placing the insider's cost basis slightly above current market. This accumulation by an established 10% stakeholder in an ultra-early-stage biomedical firm, while the company hemorrhages cash, represents a contrarian positioning into a highly speculative asset at or near IPO pricing with minimal operating revenue and persistent losses to examine.